N/A N=756 Views on COVID-19 and Vaccination
Covid19
Primary: Number of Participants Who Became Less Hesitant About the COVID-19 Vaccine After Receiving a Physician Message — 23; 26; 43; 35 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,188 The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
COVID-19 · Vaccine-Preventable Diseases · SARS CoV 2 Infection
Primary: Number of Symptomatic SARS-CoV-2 Infections Between Randomized, Study-vaccinated Participants and the Comparator Group — 48; 94 Participants
Phase 4 N=539 COVID-19 Vaccination of Immunodeficient Persons (COVAXID)
Covid19
Primary: Assessment of Seroconversion, Defined as Development of Immunoglobulin G (IgG) Antibodies Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) After…
N/A N=11,834 The Impact of Vaccination on Severity of Illness in COVID-19
Covid19
Primary: Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test — 10880; 825; 129 Participants
N/A N=338,718 Developing and Testing a COVID-19 Vaccination Acceptance Intervention
COVID-19 Vaccination
Primary: Receipt of Any Dose COVID-19 Vaccination — 57621; 65407 Participants — p=0.202
Phase 1 N=185 Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants
N/A N=6 COVID-19 Messaging for Vaccination
Vaccination Refusal · COVID-19 Pandemic
Primary: Changes in County-Level Covid-19 Vaccination Measured by Inverse Hyperbolic Sine — 0; -0.023; -0.007; -0.037 asinh(new dose 1s of vaccine)
Phase 1 N=120 Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
COVID-19 · COVID-19 Immunisation
Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants
N/A N=2,701 COVID-19 Vaccination Take-Up
Covid19 · Vaccination
Primary: Rate of COVID-19 Vaccination at 1 Month — 12; 4; 0; 1 Participants
N/A N=251 COVID-19 Vaccine Uptake Trial
Vaccination Refusal · COVID-19
Primary: Vaccine Uptake — 1; 3; 1; 0 Participants
Phase 1 N=99 Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants
Phase 4 N=66 Vaccination for Recovered Inpatients With COVID-19 (VATICO)
Covid19
Primary: Ratio of 48-Week to Baseline Neutralizing Antibody (NAb) Levels — 0.3722; 0.5883; 0.2088; 0.3073 ratio of geometric mean responses
Phase 4 N=335 Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
Quality of Life · Injection Site Reaction · Adverse Drug Event
Primary: Total Number of Participants With Moderate or More Severe Fever, Chills, Myalgia, or Arthralgia in the Simultaneous Group and the Sequential Group Following Both…
Phase 3 N=8,795 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
Influenza · COVID-19
Primary: Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine Extremity — 74.7; 59.1 Percentage of…
Phase 2 N=686 COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
N/A N=1,419 Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression
Misinformation · Vaccine Hesitancy · Anxiety
Primary: Self-reported Receipt of COVID Vaccine Dose by 4 Weeks Post-intervention — 4; 7; 6; 462 Participants
N/A N=308 COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations
Immunodeficiencies · Immune Dysregulations
Primary: Change in S and Receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody Titer From Baseline Depending on Vaccine Manufacturer and Platform — 0.447333; 2.10678…
Phase 2 N=256 Study of AZD1222 for the Prevention of COVID-19 in Japan
COVID-19
Primary: Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay — 100.0; 0.0; 100.0; 0.0…
Phase 2 N=15 A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Solid Tumor Malignancy · Hematologic Malignancy · Leukemia
Primary: Number of Participants With Grades 1-5 Solicited (Expected) and/or Unsolicited (Unexpected) Adverse Events (AE's): Initial Phase — 0; 0; 1; 0 Participants
N/A N=59 COVID-19 Vaccine Response in Sickle Cell Disease
Sickle Cell Disease · COVID-19
Primary: Antibody Response to COVID-19 Vaccine in Persons With Sickle Cell Disease — 32.155 units per mL
Phase 2 N=32 COVID Protection After Transplant-Immunosuppression Reduction
Kidney Transplant Recipients · Liver Transplant Recipients
Primary: The -Fold Change in Antibody Titer (Using the Roche Elecsys® Anti-SARS-CoV-2 S Assay) From Before Receiving the Study Dose of Vaccine to 30 Days After the Study Dose of…
N/A N=2,097 Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention
Vaccine Refusal
Primary: Post Intervention Vaccine Intentions — 54; 47; 236; 249 Participants
Phase 1 N=120 A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)
COVID-19 Disease · SARS Pneumonia · Pneumonia, Viral
Primary: Solicited Adverse Events — 88.0; 68.0; 88.0; 80.0 percent of participants
Phase 3 N=1,453 A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
SARS-CoV-2 Infection · COVID-19
Primary: Cohort 1: Percentage of Participants Reporting Local Reactions Within 7 Days After Study Vaccination — 5.8; 5.9; 3.8; 3.9 Percentage of participants
Phase 3 N=150 A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
Coronavirus Disease (COVID-19)
Primary: Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in…
N/A N=1,277,747 COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
Immunocompromised · Immunosuppressed · Covid-19
Primary: Incidence Rate of Breakthrough Cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection — 0.89; 0.34 Events per 100 person-years
Phase 2 N=644 A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
Influenza, Human · SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination — 56.3; 11.9; 59.0; 38.5 Percentage of participants
N/A N=6,911 VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination
Immunization; Infection · Pregnancy Related · COVID-19
Primary: Rate of COVID-19 Vaccination (6 Month) — 251; 130 Participants
N/A N=3,671 Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
Covid19 · Vaccine Refusal
Primary: Number of Participants Who Received a Booster Vaccination Through the Targeted Visit — 164; 146; 166 Participants
Phase 4 N=1,051 Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California
Vaccine Refusal · Covid19
Primary: Change in Vaccine Hesitancy — 282; 387; 57; 48 Participants